Company Overview and News
On April 10, 2018, Celanese (CE) announced price hikes for several products. These price hikes are effective immediately or according to the respective contracts. This price increase is expected to impact the Asia Outside China region. Below are the details of the price increases:
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process.
The First Trust Materials AlphaDEX Fund (FXZ - Free Report) made its debut on 05/08/2007, and is a smart beta exchange traded fund that provides broad exposure to the Materials ETFs category of the U.S. equity market.
The shale gas revolution in the United States has been a huge driving force behind chemical investments in plants and equipment in the country. And currently, the U.S. petrochemical industry is in the middle of a shale-induced investment boom leveraging access to abundant and cheaper feedstocks. However, the escalating trade tensions between Washington and Beijing is expected to play spoilsport. President Donald Trump, who has a record of attacking China for unfair trade practices, recently proposed sweeping tariffs on $50 billion of imports from China.
In 2017, Celanese (CE) incurred interest expenses of $122 million—marginally less compared to $126 million in fiscal 2016. Celanese’s interest expense has been declining since 2013 despite the increase in its overall debt. The decrease in Celanese’s interest expense is mainly due to its refinancing activities. The company’s refinancing replaced the highest coupon rate debts with low coupon rate debts.
At the end of 2017, Celanese (CE) reported debt of $3.64 billion—compared to $3.06 billion in 2016. On a year-over-year basis, Celanese’s debt increased 18.2% due to issuing 300 million euros to fund its qualified US pension plans. Between 2012 to 2014, Celanese debt showed a declining trend. Since 2015, Celanese’s debt has been increasing gradually.
At the end of 2017, Eastman Chemical (EMN) reported debt of $6.54 billion compared to $6.59 billion in 2016. Though the debt remained more or less the same on a year-over-year basis, it has been sliding down since 2015. EMN’s debt has fallen from $7.55 billion in 2014 to the present $6.59 billion, which indicates the company has started the deleveraging process and we can expect it to get better and better with steady free cash flow in place.
A company’s Zacks Rank is a great indication of how well it’s expected to perform over the next one to three months. Here at Zacks, we discuss how this ranking tool helps identify the best of the best, as only 5% of the Zacks Rank universe receives the exclusive rating of a #1 (Strong Buy).
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET